MARKET

JAGX

JAGX

Jaguar Health Inc
NASDAQ
0.9975
+0.0663
+7.12%
After Hours: 0.9800 -0.0175 -1.75% 19:56 01/02 EST
OPEN
0.9493
PREV CLOSE
0.9312
HIGH
1.020
LOW
0.9239
VOLUME
232.58K
TURNOVER
--
52 WEEK HIGH
33.25
52 WEEK LOW
0.9174
MARKET CAP
4.17M
P/E (TTM)
-0.0185
1D
5D
1M
3M
1Y
5Y
1D
Jaguar Health awarded $240,000 FDA grant in support of Canalevia-CA1
TipRanks · 2d ago
Jaguar Health Awarded $240K Grant From FAD's Center For Veterinary Medicine
Benzinga · 2d ago
Jaguar Health Secures $240,000 FDA Grant for Canalevia-CA1 Chemotherapy-Induced Diarrhea Study in Dogs
Reuters · 2d ago
Weekly Report: what happened at JAGX last week (1222-1226)?
Weekly Report · 12/29/2025 10:12
Weekly Report: what happened at JAGX last week (1215-1219)?
Weekly Report · 12/22/2025 10:12
Jaguar Health announces abstract submission for crofelemer preliminary data
TipRanks · 12/15/2025 14:21
Jaguar Health's Napo Pharma's Independent Investigator At SBS-IF Treatment Institution Submits Abstract Describing Preliminary Findings From Clinical Trial Evaluating Oral Liquid Formulation Of Crofelemer In Adult SBS-IF Patients
Benzinga · 12/15/2025 14:07
Jaguar Health Announces Preliminary Clinical Trial Results for Crofelemer in Short Bowel Syndrome
Reuters · 12/15/2025 14:00
More
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Webull offers Jaguar Health Inc stock information, including NASDAQ: JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.